You can buy or sell MLNT and other stocks, options, ETFs, and crypto commission-free!
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. Read More These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in New Haven, CT.
New Haven, Connecticut
52 Week High
52 Week Low
Seeking AlphaMar 13
Melinta Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides
The following slide deck was published by Melinta Therapeutics, Inc. in conjunction with their 2018 Q4 earnings call. 1 14 Click to enlarge Notes:...
Yahoo FinanceMar 13
Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Melinta Therapeutics, Inc. (MLNT) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $7.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of...
Associated PressMar 5
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financi...
-$4.33 per share
-$1.70 per share